Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis by Filomena Morisco et al.
Morisco et al. BMC Gastroenterology 2014, 14:214
http://www.biomedcentral.com/1471-230X/14/214RESEARCH ARTICLE Open AccessLack of evidence of viral reactivation in
HBsAg-negative HBcAb-positive and HCV
patients undergoing immunosuppressive
therapy for psoriasis
Filomena Morisco1*, Maria Guarino1, Serena La Bella2, Luisa Di Costanzo2, Nicola Caporaso1, Fabio Ayala2
and Nicola Balato2Abstract
Background: HBV and HCV reactivation have been widely reported in patients undergoing immunosuppressive
therapy (IT); however, few data are available on the risk of reactivation in patients with psoriasis receiving IT. The aim
of our study was to assess the prevalence of HBV and HCV infection in patients with psoriasis and to evaluate the
effects of IT during the course of the infection.
Methods: The study included psoriatic patients who attended an Italian tertiary referral hospital from 2009 to
2012. A total of 224 patients were enrolled. We evaluated: HBV and HCV markers, type of IT and the occurrence
of viral reactivation. The observational period ranged from the beginning of IT to the last visit, with a mean
follow-up period of 54 months.
Results: Two hundred and twenty patients (135 males and 89 females; mean age 59 years; range 18? 86 years)
with psoriasis, with or without psoriatic arthritis, receiving conventional IT and/or biological drugs were tested for
markers of infection. We identified 23/224 patients (10.2%) with isolated positivity for HBcAb positivity, 36/224
(16%) with positivity for HBsAb/HBcAb, and 15/224 (6.6%) with positivity for HCV-Ab. No patient was HBsAg positive,
none of them underwent pre-emptive therapy with lamivudine or other antiviral drugs and no one showed episodes
of viral reactivation.
Conclusions: The prevalence of HBsAg in patients with psoriasis is lower than that observed in the general
population. The prevalence of isolated positivity for HBcAb and of combined positivity for HBcAb and HBsAb is
10.2% and 16%, respectively. The prevalence of HCV infection (HCV-RNA+) is 4%. In patients with psoriasis and
HCV-Ab or HBcAb positivity, the IT seems to be safe, regardless of the type of drugs.
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Psoriasis is a chronic, immune-mediated relapsing and re-
mitting inflammatory skin and joint disease. The preva-
lence of psoriasis estimates as high as 2.8% in western
populations [1,2]. Currently, different immunosuppressive
therapeutic regimens are indicated for patients with psor-
iasis. The best treatment is determined on an individual* Correspondence: filomena.morisco@unina.it
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unless otherwise stated.basis and depends on the type of disease, the Psoriasis
Area Severity Index (PASI) and comorbidities. For mild
disease (PASI <10), involving only small areas of the body,
topical treatments such as corticosteroids or calcineurin
inhibitors or vitamin D derivates may be very effective and
safe to use [3]. Up to 30% of 70% of psoriatic patients
(PASI >/=10 that involves much larger areas of the body
or for psoriatic artrhritis), require traditional systemic
treatments such as retinoids, methotrexate and cyclospor-
ine. Many of them imply long-term toxicity, treatment
resistance and potential drug interactions; therefore, onlyThis is an Open Access article distributed under the terms of the Creative
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treatment [4]. Advances in psoriasis therapies have intro-
duced biologic agents, whose immune targeting is suc-
cessful in treating many immunemediated inflammatory
diseases [4]. Psoriatic patients who are refractory or in-
tolerant to traditional therapy are the main candidates
for biological anti-tumor necrosis factor alpha (TNF-a)
drugs, for instance, infliximab, adalimumab, etanercept,
golimumab or the anti-IL-12/23p40 monoclonal antibody,
such as ustekinumab [5]. Several reports and studies have
highlighted the risk of adverse events related to immuno-
suppressive therapy (IT) [4]. Under immunosuppression
conditions, all patients with a history of exposure to HBV
or HCV are at risk of reactivation [6-18]. The widespread
use of biological drugs have raised these issues concerning
the safety and the potential risks related to its administra-
tion, including patients with psoriasis [19-28]. Although a
large amount of information on the relationship between
IT for psoriasis and the behavior of HBV/HCV infections
have become more available, the impact of different im-
munosuppressive drugs on the risk of reactivation remains
poorly investigated.
The aim of our study was to assess the prevalence of
HBV and HCV infection in a consecutive series of pa-
tients with psoriasis and to evaluate the effects of differ-
ent schedules of immunosuppressive therapy during the
course of the infection.
Methods
This is a retrospective, observational study carried out at
the Dermatology Unit of the University of Naples ? Federico
II,? a tertiary referral centre in Southern Italy. The target
population consisted of adult patients with plaque-type
psoriasis (Pso) with or without psoriatic arthritis (PsA) can-
didate to immunosuppressive therapy, observed from 1
January 2009 to 31 December 2012.
This study was independently designed by the authors,
conducted in compliance with the 1975 Declaration of
Helsinki and approved by the Ethic Committee of the
University of Naples Federico II (protocol n? 175/2012).
Records for 224 outpatients were reviewed in relation
to the markers of previous disease or active HBV and
HCV infection. Among them, patients with almost 1
positive marker of HBV or HCV infection were identified
for the inclusion in the study. All of the selected patients
underwent immunosuppressive therapy, such as conven-
tional immunosuppressive treatment (cyclosporine A,
methotrexate (MTX)) or biological treatment (adalimu-
mab, etanercept, infliximab, golimumab, ustekinumab) or
combined biological plus methotrexate. The medical re-
cords of these selected patients were retrospectively
reviewed.
Before starting the immunosuppressive therapy, all
psoriatic patients had been routinely tested for serologyof HBV and HCV infection. For patients with HBV or
HCV infection, a scheduled monitoring had been applied:
transaminases every 1 month, complete liver function test
(bilirubin, INR, γ-Glutamyltransferase, alkaline phosphat-
ase, albumin) every 3 months and HBV/HCV serological
status (HBsAg and HBV-DNA for HBV infection, HCV-
RNA for HCV infection) every 3 months from the start of
therapy, until the last follow-up visit.
Definition of HBV and HCV infection
HBV chronic infection was defined according to the
EASL guidelines [29] as patients positive for HBsAg, in-
dependently from the HBeAg/HBeAb positivity and the
levels of HBV-DNA. ? Occult ? HBV infection (OBI) rep-
resents a particular clinical entity that is characterized
by the persistence of HBV DNA in the liver tissue, with-
out the evidence of overt HBV infection in individuals
who are HBsAg negative and HBcAb positive either with
or without serum HBV-DNA positivity [29]. The diffi-
culty in identifying HBV-DNA in liver biopsy (frequently
not justified in patients without clinical signs of hepatitis)
and the rarity of detectable serum viremia, even with sensi-
tive techniques, lead to consider all HBcAb positive pa-
tients (HBsAg and HBV-DNA negative, with or without
HBsAb positivity) as potential OBI. Patients with HBsAg
negativity but positivity for HBcAb with HBsAb positivity,
were considered as a resolved HBV infection [29].
Potential OBI and resolved HBV infection were analyzed
for the same parameters as the HBsAg-positive patients.
HCV infection was defined as patients positive for anti-
HCV, with or without positivity for HCV-RNA [30].
Definition of HBV and HCV reactivation
In HBV- positive patients, the following biochemical events
were considered significant for a viral reactivation:
? in HBsAg-positive patients (active or inactive carriers),
the increase of at least one logarithm of HBV-DNA
with or without the concomitant increase of
transaminases;
? in potential OBI and resolved HBV infection
(HBsAb positive and/or HBcAb positive patients),
the re-emergence of HBsAg or the appearance or
increase of at least one logarithm of HBV-DNA.
Reactivation of HCV was defined as a significant increase
of HCV-RNA (at least one logarithm), with or without a
concomitant increase of transaminases. In HCV-Ab posi-
tive but HCV-RNA negative patients, the re-appearance of
HCV-RNA was considered as a relevant event.
Serological profile
HBsAg, HBcAb and HBsAb were determined by conven-
tional commercial assay kits (Abbott AxSYM AUSAB,
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Ab and HDV-Ab were determined by commercial enzyme
linked immunosorbent assay III, Abbot Laboratories
Chicago. All HBcAb-positive samples were assayed for
serum HBV-DNA by a commercial qualitative target amp-
lification method (Cobas Ampliscreen, Roche Molecular
Systems, Branchburg, New Jersey, USA). In order to
achieve the highest sensitivity allowed by this method
(20 IU/mL), testing was performed on each individual sam-
ple without pooling and increasing the volume for extrac-
tion (500 μL). The specimens that resulted positive were
further tested by a quantitative method (Cobas Amplicor
HBV Monitor, Roche Molecular Systems, Branchburg, NJ,
USA) to determine the viral load.
All HCV-Ab positive samples were assayed for serum
HCV-RNA by a qualitative method (Cobas Ampliscreen,
Roche Molecular Systems, Branchburg, New Jersey, USA).
In order to achieve the highest sensitivity allowed by this
method (15 IU/mL), testing was performed on each indi-
vidual sample - without pooling- and increasing the
volume for extraction (500 μL). The specimens that re-
sulted positive were further tested by quantitative method
(Light Cycler Instrument, Roche Molecular Biochemicals,
Mannheim, Germany) to determine the viral load.
Statistical analysis
Demographical, clinical, biochemical, histological, viro-
logical and therapeutic data were collected from medical
records by case report forms. Baseline characteristics
were expressed as median and range for continuous and
not normally distributed data, as a mean and standard
deviation (SD) for normally distributed data and as a
percentage for categorical data.
Results
Seventy-four patients with plaque-type psoriasis (Pso)
with or without psoriatic arthritis (Psa) and with active
or previous HBV or HCV infection were identified in a
population of 224 patients, receiving conventional orTable 1 Characteristics of patients with psoriasis at baseline
Overall Isolated HBcA
N? of patients 224 23
Age, yrs (mean ? SD) 49 [?13.3] 66 [?10.6
Gender (M/F) N?% 135/89 [60.2/39.7%] 10/13 [43.4
Pso 113 [50.5%] 10 [43.
PsA 111 [49.5%] 13 [56.
ALT, U/L (mean ? SD) 23 [?5.3] 27 [?2.3]
HBV-DNA positivity 0/224 0/23
HCV-RNA positivity 9/224 0/23
HBsAg positivity 0/224 0/23biological treatment. All of these patients are still being
treated for psoriasis. The characteristics of our popula-
tion are illustrated in Table 1.
HBV infection
No patient was HBsAg positive. Globally, 59 patients
showed almost 1 marker of HBV infection; 23/224
(10.2%) patients were isolated HBcAb positive (OBI) and
36/224 (16%) patients were HBsAb and HBcAb positive
(resolved HBV infection). The main features of the 59
patients are reported in Table 1. Thirty-two patients
were affected by plaque-type psoriasis and 27 by psori-
atic arthritis. None of them showed signs of cirrhosis. At
baseline all patients had normal aminotransferase levels
and negative HBV-DNA. All HBV patients underwent
immunosuppressive therapy. The treatment schedules
are reported in Table 2. Nineteen patients (32%) were
treated with conventional drugs only (Metotrexate,
Cyclosporine or a combination of the two drugs) for a
mean time of 24 months, 34 patients (58%) were treated
with conventional and biological drugs, sequentially, for
a mean time of 42 months, and 6 patients (10%) were
treated with conventional drugs followed by a combin-
ation of biological drug plus methotrexate) for a mean
time of 72 months. No patients were treated with
prophylactic Lamivudine. In all of the cases serum liver
functional tests showed no significant changes in AST
or ALT levels and HBV-DNA positivity, from baseline to
the last follow-up visit.
HCV infection
Overall, 15/224 (6.6%) patients had a positive serology
for anti-HCV (11 males and 4 females, mean age 62 yrs).
The main features of the 15 patients with HCV infection
are reported in Table 1. Nine patients were affected by
plaque-type psoriasis and 6 by psoriatic arthritis. None
of them showed signs of cirrhosis. All HCV patients had
baseline normal aminotransferase levels, 6/15 were HCV-
RNA negative and 9/15 were positive (mean levels ofb positive HBcAb/HBsAb positive HCV-Ab positive
36 15
] 52 [?12.4] 62 [?11.8]
/56.5%] 27/9 [75/25%] 11/4 [73.3/26.6%]
5%] 22 [61.1%] 9 [60%]
5%] 14 [38.9%] 6 [40%]




Table 2 Schedules of treatment in patients with HBV or HCV infection







MTX, n. 3 5 0
Duration, months (mean ? SD) 11 ? 7,54 24 ? 23,62 -
Cyclosporine, n. 0 4 4
Duration, months (mean ? SD) - 5,75 ? 4,5 20,25 ? 10,34
MTX + Cyclosporine, n. 2 5 5
Duration, months (mean ? SD) 12 26,4 ? 21,46 30,4 ? 22,19
Conventional > Biological* therapy, n. 16 18 6
Duration, months (mean ? SD) 33,8 ? 16,9 48,1 ? 26,55 46 ? 34,77
Conventional > Biological* therapy +MTX, n. 2 4 0
Duration, months (mean ? SD) 35,5 ? 4,94 90,75 ? 65,06 -
*Adalimumab, etanercept, infliximab, golimumab, ustekinumab.
[#] The treatment schedule was standardized, the doses were used as follows.
● MTX (7.5 vs15 mg/ week -per os or intramuscular injections).
● Cyclosporine (2.5 vs 5 mg/prokilo/die- per os).
● Adalimumab (40 mg every other week-subcutaneous injections).
● Etanercept (50 mg weekly- subcutaneous injections).
● Infliximab (5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks-endovenous infusion).
● Golimumab (50 mg monthly-subcutaneus injections).
● Ustekinumab ( For patients weighing ≤100 kg (220 lbs), the recommended dose is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks. For
patients weighing >100 kg (220 lbs), the recommended dose is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks. ? subcutaneous injections).
The data in bold represent "macro-categories", while the data not in bold represent their "sub-categories".
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and underwent immunosuppressive therapy. The schedules
of treatment are reported in Table 2. Nine patients (60%)
were treated with conventional drugs only (Metotrexate,
Cyclosporine or a combination of the two drugs) for a
mean time of 26 months and 6 patients (40%) were treated
with conventional and biological drug, sequentially, for a
mean time of 46 months. Serum liver functional tests in all
cases showed no significant changes in AST or ALT levels
and in viral load, from baseline to the last follow-up visit.
Discussion
The reactivation of viral hepatitis, in particular HBV dis-
ease, has been widely reported in patients undergoing IT
in different clinical conditions with particular frequency
and severity in onco-haematological and transplant set-
tings._Conversely, very few data are available in litera-
ture on the course of liver disease and the risk of HBV
or HCV reactivation in patients with psoriasis receiving
IT [19-25], the major part of them are case reports and
series of patients.
Our study is the first observational analysis conducted in
a larger cohort of psoriatic patients with a serological pat-
tern of active or previous HBV or HCV infection, assessing
the safety of different schedules of immunosuppressive
therapy for a mean follow-up period of 48 months.
The main results of our investigation is represented by
the absence of episodes of viral reactivation in HBsAgnegative-HBcAb positive patients independently of the type
of immunosuppressive (conventional or biological) drugs.
The risk of reactivation for the category of potential
occult HBV infection is controversial and might be re-
lated to the clinical setting and type of IT. There are
several reported cases of HBV reactivation in HBcAb
positive patients with and without concomitant HBsAb
positivity in patients who have undergone bone marrow
transplantation or cytotoxic chemotherapy for lymph-
oma [31]. In these patients, the use of intense immuno-
suppression, monoclonal antibodies anti-lymphocyte B
and T (anti-CD20) are particularly considered as risk
factors. Conversely, in other clinical settings (gastro-
enterology, rheumatology and dermatology) the risk of
reactivation in isolated HBcAb positive patients seems to
be negligible or absent [20,22,32,33].
Our result seems to be in agreement with other previ-
ous reports limited by the observation of a small
number of patients using biological agents for a short
follow-up period. For example, the study of Prignano
et al. [23] conducted in a cohort of 17 patients with
psoriasis, using etanercept and/or adalimumab showed
no significant changes in aminotransferase and in viral
load levels during a follow-up period of only 6? 8 months.
Moreover, in the latest study by Navarro et al. [28],
the safety of anti-TNF agents in 13 psoriatic HBsAg
negative ? HbcAb positive patients during a mean follow-
up time of 28.6 months has been pointed out, suggesting
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infection.
Concerning patients with resolved HBV infection (HBsAg
negative, HBcAb positive, HBsAb positive), there is only
one reported case of viral reactivation in a dermato-
logical setting during immunosuppressive therapy with
ustekinumab, as described by Koskinas et al. [19]. In our
study, no viral reactivation was observed in this category,
confirming a low risk of viral reactivation in resolved
HBV infection.
On the other hand, more data are available in litera-
ture for patients with chronic HBV infection (HBsAg
positive). In total, 103 patients HBsAg positive with
concomitant psoriasis and IT have been described in lit-
erature [20,24,25,34,35]; 56/103 of these patients were
treated with concomitant antiviral therapy and only 5/56
(8.9%) showed HBV reactivation [35]. Differently, among
the remaining patients without antiviral prophylaxis,
32/47 (68%) patients showed HBV reactivation during
biological therapy [25,35]. We did not observe HBsAg
positive patients in our series of patients; therefore, we
can add nothing to what is already known in this category,
which seems to be the only one at high risk of reactivation
during biological therapies. In this perspective, the Euro-
pean guidelines for the use of anti-TNF therapy in psoria-
sis published in 2009 [36], the British Association of
dermatologist guidelines for the use of biological interven-
tions in psoriasis published in 2005 [37] and the Japanese
guidance for use of biologics for psoriasis published in
2013 [38] consider active chronic hepatitis B as relative or
absolute contraindication to the use of anti-TNF agents.
Considering the success of biological IT in HBsAg patients
using concomitant antiviral therapy, these guidelines seem
far from clinical reality and current evidence. Only 5 cases
of HBV reactivation in psoriatic patients treated with bio-
logical drugs (3 etanercept and 2 infliximab), using con-
comitant antiviral therapy (lamivudine) are reported in
literature until now [35].
The prophylactic use of antiviral drugs is an important
issue. Lamivudine prophylaxis has been suggested on the
basis of its well demonstrated efficacy; however, other
nucleotides/nucleosides should be preferred for their
lower propensity to provoke drug resistance, especially if
immunosuppressive therapy is scheduled for more than
12 months. The role of alternative anti-viral drugs, in-
cluding entecavir and tenofovir, is still unknown and fur-
ther studies are needed.
With regard to patients with HCV infection, the use of
IT appears to induce lower frequency and severity of
viral reactivation than in HBV. This finding is confirmed
in our series of 15 HCV patients undergoing IT in which
no viral reactivation was observed. Only one case of HCV
reactivation during treatment with ustekinumab for psoria-
sis is reported in the literature [25].Conclusions
In conclusion, screening for HBV and HCV is now rec-
ommended for all patients with psoriasis, before starting
all types of IT therapy. All patients with psoriasis should
be tested for HBV (including HBsAg, HBcAb, HBsAb
and HBV-DNA if needed) and HCV (including HCV-Ab
and HCV-RNA if HCV-Ab positive) to assess the infec-
tion or vaccination status. HBV vaccination is mandatory
in all seronegative patients. The current data that are
available suggest that anti-TNFα and IL-12 and IL-23
blockers may also represent a therapeutic option in pa-
tients with concomitant HBV and/or HCV infection.
The risk of HBV or HCV reactivation related to TNFα
inhibitors seems to be low. The best strategy to adopt in
HBsAg negative/HBcAb positive patients with or without
HBsAb positivity and HCV positive patients would ap-
pear to be represented by periodic clinical and laborator-
istic monitoring.
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